EGFR and NF-κB: Partners in cancer

Trends in Molecular Medicine

Volumn 21, Issue 6, 2015, Pages 385-393

  Shostak, Kateryna ^a   Chariot, Alain ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Walloon Excellence in Life Sciences and Biotechnology (WELBIO)   (Belgium)

Author keywords

EGFR; Erlotinib; Gefitinib; NF B; Resistance; Tumor initiating cells

Indexed keywords

BORTEZOMIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ERLOTINIB; KIAA1199 PROTEIN, HUMAN; PROTEIN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ENZYME ACTIVATION; ENZYME ACTIVITY; GENE TARGETING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

ANIMALS; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84930542408     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.04.001     Document Type: Review

References (82)

1. Sordella R., et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
2. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
3. Shoelson S.E. SH2 and PTB domain interactions in tyrosine kinase signal transduction. Curr. Opin. Chem. Biol. 1997, 1:227-234.
4. Morandell S., et al. Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 2008, 8:4383-4401.
5. Lowenstein E.J., et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992, 70:431-442.
6. Okutani T., et al. Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. J. Biol. Chem. 1994, 269:31310-31314.
7. Sakaguchi K., et al. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. Mol. Endocrinol. 1998, 12:536-543.
8. Olayioye M.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
9. Wykosky J., et al. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin. J. Cancer 2011, 30:5-12.
10. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
11. Kris M.G., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
12. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
13. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
14. Ekstrand A.J., et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991, 51:2164-2172.
15. Wong A.J., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2965-2969.
16. Sharma S.V., et al. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
17. Cheng L., et al. Molecular pathology of lung cancer: key to personalized medicine. Mod. Pathol. 2012, 25:347-369.
18. Kobayashi S., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
19. Yu H.A., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19:2240-2247.
20. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6:714-727.
21. Zhou W., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
22. Quesnelle K.M., Grandis J.R. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin. Cancer Res. 2011, 17:5935-5944.
23. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
24. Sergina N.V., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
25. Wheeler D.L., et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
26. Pinkas-Kramarski R., et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996, 15:2452-2467.
27. Campbell M.R., et al. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin. Cancer Res. 2010, 16:1373-1383.
28. Ma J., et al. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol. Cancer 2014, 13:105.
29. Ghosh S., Hayden M.S. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 2008, 8:837-848.
30. Biswas D.K., et al. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8542-8547.
31. Sun L., Carpenter G. Epidermal growth factor activation of NF-kappaB is mediated through IkappaBalpha degradation and intracellular free calcium. Oncogene 1998, 16:2095-2102.
32. Biswas D.K., et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10137-10142.
33. Le Page C., et al. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 2005, 65:130-140.
34. Yang W., et al. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell 2012, 48:771-784.
35. Jiang T., et al. CARMA3 is crucial for EGFR-Induced activation of NF-kappaB and tumor progression. Cancer Res. 2011, 71:2183-2192.
36. McAllister-Lucas L.M., et al. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:139-144.
37. Mahanivong C., et al. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008, 27:1273-1280.
38. Thome M. Multifunctional roles for MALT1 in T-cell activation. Nat. Rev. Immunol. 2008, 8:495-500.
39. De S., et al. EGF receptor uses SOS1 to drive constitutive activation of NFkappaB in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:11721-11726.
40. Zhao C., et al. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat. Cell Biol. 2007, 9:706-712.
41. Shostak K., et al. NF-kappaB-induced KIAA1199 promotes survival through EGFR signalling. Nat. Commun. 2014, 5:5232.
42. Kuscu C., et al. Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer. PLoS ONE 2012, 7:e44661.
43. Nottingham L.K., et al. Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 2014, 33:1135-1147.
44. Ramnarain D.B., et al. RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR. Cell Death Differ. 2008, 15:344-353.
45. Bentires-Alj M., et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97.
46. Guo C., Stark G.R. FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7968-7973.
47. Kim L., Wong T.W. Growth factor-dependent phosphorylation of the actin-binding protein cortactin is mediated by the cytoplasmic tyrosine kinase FER. J. Biol. Chem. 1998, 273:23542-23548.
48. Kim L., Wong T.W. The cytoplasmic tyrosine kinase FER is associated with the catenin-like substrate pp120 and is activated by growth factors. Mol. Cell. Biol. 1995, 15:4553-4561.
49. Bivona T.G., et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
50. Dermawan J.K., et al. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-kappaB, and cell-cycle progression in non-small cell lung cancer. Mol. Cancer Ther. 2014, 13:2203-2214.
51. Dean M., et al. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
52. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
53. Seguin L., et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 2014, 16:457-468.
54. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.
55. Tanaka K., et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 2011, 1:524-538.
56. Puliyappadamba V.T., et al. Opposing effect of EGFRWT on EGFRvIII-mediated NF-kappaB activation with RIP1 as a cell death switch. Cell Rep. 2013, 4:764-775.
57. Kusne Y., et al. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFalpha in glioblastoma. Sci. Signal. 2014, 7:ra75.
58. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin. Cancer Res. 2007, 13:1076-1082.
59. Vermorken J.B., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 2007, 25:2171-2177.
60. Wheeler S.E., et al. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010, 29:5135-5145.
61. Wheeler S.E., et al. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin. Cancer Res. 2012, 18:2850-2860.
62. Pernas F.G., et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin. Cancer Res. 2009, 15:2361-2372.
63. Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest. 2004, 22:304-311.
64. Allen C., et al. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin. Cancer Res. 2008, 14:4175-4185.
65. Allen C.T., et al. CCR 20th Anniversary Commentary: preclinical study of proteasome inhibitor bortezomib in head and neck cancer. Clin. Cancer Res. 2015, 21:942-943.
66. Argiris A., et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin. Cancer Res. 2011, 17:5755-5764.
67. Sloss C.M., et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 2008, 14:5116-5123.
68. Skaar J.R., et al. SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov. 2014, 13:889-903.
69. Kobori M., et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 2004, 11:123-130.
70. Hertlein E., et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010, 116:45-53.
71. Hu J.C., et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J. Am. Acad. Dermatol. 2007, 56:317-326.
72. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 2006, 6:803-812.
73. Mascia F., et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci. Transl. Med. 2013, 5:199ra110.
74. Lichtenberger B.M., et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci. Transl. Med. 2013, 5:199ra111.
75. Lee D.F., Hung M.C. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res. 2008, 14:5656-5662.
76. Karin M., et al. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3:17-26.
77. Verstrepen L., Beyaert R. Receptor proximal kinases in NF-kappaB signaling as potential therapeutic targets in cancer and inflammation. Biochem. Pharmacol. 2014, 92:519-529.
78. Popovic D., et al. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 2014, 20:1242-1253.
79. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
80. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 2014, 79:34-74.
81. Hayden M.S., Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26:203-234.
82. Chen J., Chen Z.J. Regulation of NF-kappaB by ubiquitination. Curr. Opin. Immunol. 2013, 25:4-12.